[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100389155":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":47,"collaborators":7,"id":49,"slug":7,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":7,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Antiplatelet Drug","single or dual antiplatelets, triple antithrombotic therapy",[14],"anticoagulant Drug",[16],{"name":17,"affiliation":5,"role":18},"Elizaveta Panchenko, PhD","PRINCIPAL_INVESTIGATOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Andrey Komarov, PhD","CONTACT","+79161813257","andrkomarov@mail.ru",[26],{"facility":5,"status":27,"city":28,"state":7,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Moscow","121552","Russia",{"type":32,"coordinates":33},"Point",[34,35],37.61781,55.75204,{"lat":35,"lon":34},[38,39,42,43,45],{"name":17,"role":18,"phone":7,"phoneExt":7,"email":7},{"name":40,"role":41,"phone":7,"phoneExt":7,"email":7},"Olga Shakhmatova, PhD","SUB_INVESTIGATOR",{"name":21,"role":41,"phone":7,"phoneExt":7,"email":7},{"name":44,"role":41,"phone":7,"phoneExt":7,"email":7},"Elena Yarovaya, PhD",{"name":46,"role":41,"phone":7,"phoneExt":7,"email":7},"Alla Shuleshova, PhD",{"type":48,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100389155",false,"NCT04347200","REGistry of Long-term AnTithrombotic TherApy-1","Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes","REGATTA-1","Inclusion Criteria:\n\n* coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging\n\nExclusion Criteria:\n\n* Subjects who are unwilling or unable to provide informed consent.\n* Acute coronary syndrome within 12 months before inclusion\n* Severe chronic heart failure (NYHA IV)\n* Stroke within 6 months before inclusion\n* Severe liver or muscle disease\n* Severe kidney disease \u002F renal failure with creatinine \\> 3 mg\u002Fdl\n* Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -","ALL","18 Years",{"count":59,"type":60},2000,"ESTIMATED","5 Years","OBSERVATIONAL","To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes",[65,66],"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))","Peripheral Artery Disease",[68],"Coronary Artery Disease, Peripheral Artery Disease","2026-04-27",{"date":71,"type":72},"2026-05-01","ACTUAL",{"date":74,"type":72},"2015-01-15",{"date":76,"type":60},"2026-12-31",{"name":5,"class":6},1]